Lindy Biosciences
Research Triangle Park, US · Founded 2016 · Delaware corporation · 1 known investors
Lindy Biosciences develops biotherapeutic drug delivery technology using a proprietary Microglassification platform to reformulate antibody therapeutics into forms patients can self-administer at home instead of via intravenous infusion. It partners with pharmaceutical companies developing biotherapeutic drug products.
Founders & leadership
Lindy Biosciences was founded in 2016 by Deborah Bitterfield.
DB
Deborah BitterfieldFounder
KL
Karen LeVertNamed on SEC filing
SG
Sreekar GaddeNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$5.7M disclosed across 4 rounds · 2018–2024
▶$1.7MraisedMar 2024 · 10 investors · BiotechnologyRule 506(b)
▶$1.7MraisedMar 2024 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Karen LeVertDirector
- Omar FloresExecutive Officer, Director
- Deborah BitterfieldExecutive Officer, Director, Promoter
- Joel WhitleyDirector
- Offering amount
- $2.5M
- Amount sold
- $1.7M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.3MraisedMar 2022 · 29 investors · BiotechnologyRule 506(b)
▶$3.3MraisedMar 2022 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Karen LevertDirector
- Omar FloresDirector
- Deborah BitterfieldExecutive Officer, Director, Promoter
- Sreekar GaddeDirector
- Offering amount
- $5M
- Amount sold
- $3.3M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$547.7KraisedJan 2019 · 6 investors · BiotechnologyRule 506(b)
▶$547.7KraisedJan 2019 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Karen LeVertExecutive Officer, Director
- Sreekar GaddeDirector
- Deborah BitterfieldExecutive Officer, Director, Promoter
- Offering amount
- $1.6M
- Amount sold
- $547.7K
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$150KraisedMar 2018 · 1 investors · BiotechnologyRule 506(b)
▶$150KraisedMar 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Karen LeVertDirector
- Deborah BitterfieldExecutive Officer, Director, Promoter
- Offering amount
- $150K
- Amount sold
- $150K
- First sale
- Mar 2018
- Incorporated
- Limited Liability Company, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlapLife Biosciences6 shared keywordsLongevity company with diversified therapies to extend healthy human lifespan
Precision BioSciences5 shared keywordsPrecision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
IQVIA5 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Lime Therapeutics4 shared keywordsLime Therapeutics is a biotechnology company developing lipid-altering medicines for cancer, cardiometabolic diseases, lysosomal storage diseases, and neurodegenerative disorders. The company uses LipidSense, a proprietary ultrasensitive lipid detection platform, to discover and develop therapeutics targeting lipid dysfunction.
Lumen4 shared keywordsLumen develops orally-delivered biologic drugs using genetically engineered spirulina algae, which expresses therapeutic proteins such as enzymes, antibodies, and cytokines that are spray-dried into shelf-stable powders and capsules. Its pipeline targets conditions including weight loss, C. difficile, Crohn's disease, ulcerative colitis, and respiratory infections.
AmideBio3 shared keywordsAmideBio uses in-silico design and proprietary peptide synthesis to develop preclinical peptide drug candidates for metabolic disease. It also offers custom peptide synthesis services and a catalog of high-purity peptides for customers.
Bioworld3 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Lindy Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Lindy Biosciences do?
- Lindy Biosciences develops biotherapeutic drug delivery technology using a proprietary Microglassification platform to reformulate antibody therapeutics into forms patients can self-administer at home instead of via intravenous infusion. It partners with pharmaceutical companies developing biotherapeutic drug products.
- Who founded Lindy Biosciences?
- Lindy Biosciences was founded by Deborah Bitterfield in 2016.
- Who are Lindy Biosciences's investors?
- Lindy Biosciences's investors include Good Growth Capital.
- How much funding has Lindy Biosciences raised?
- Lindy Biosciences has disclosed $5.7M raised across 4 rounds.
- Where is Lindy Biosciences headquartered?
- Lindy Biosciences is headquartered in Research Triangle Park, US.